There was a significant increase in the frequency of RUNX1 mutations towards progression/transformation of CMML into AML but no increase in the prevalence of mutations of SETBP1, TET2, EZH2, ASXL1, SRSF2, and TP53. Here, SRSF2 is linked to chronic myelomonocytic leukemia.